Azome Therapeutics:
Developing a compelling narrative for potential investors
Background
Azome Therapeutics is an early-stage drug discovery company focused on advancing treatment of severe inflammatory diseases. The company’s RHAMM-antagonist platform blocks NLRP3 inflammasome activation, and its lead drug candidate, AZM-152, has demonstrated significant preclinical potential in a number of severe inflammatory diseases, including several that have significant unmet needs.
Approach
Since mid 2023, NVision has been working closely with Azome leadership to develop a compelling narrative for potential investors. This has included new branding, a new website, and presentation materials as well as the development and management of an ongoing and consistent newsflow of information, designed to differentiate the company and its core platform technology.
